The value of prognostic factors in small cell lung cancer: results from a randomised multicenter study with minimum 5 year follow-up

被引:146
作者
Bremnes, RM [1 ]
Sundstrom, S
Aasebo, U
Kaasa, S
Hatlevoll, R
Aamdal, S
机构
[1] Univ Tromso Hosp, Dept Oncol, N-9038 Tromso, Norway
[2] Univ Trondheim Hosp, Dept Oncol, N-7007 Trondheim, Norway
[3] Univ Tromso Hosp, Dept Pulm Med, N-9038 Tromso, Norway
[4] Norwegian Radium Hosp, Dept Oncol, N-310 Oslo, Norway
关键词
SCLC; limited disease; extensive disease; prognostic factors; survival;
D O I
10.1016/S0169-5002(02)00508-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
We have evaluated the prognostic value of 22 pretreatment attributes in 436 small cell lung cancer (SCLC) patients included in a prospective multicenter study with a minimum 5-year follow-up. Pretreatment clinical and laboratory parameters were registered. Possible prognostic factors were evaluated by univariate analysis (log rank test) and by the Cox multivariate regression model. In the univariate analysis of all patients, only age, nodal metastasis, and skin metastasis were not associated with survival. The multivariate Cox model identified gender, extent of disease, performance status (PS), weight loss, platelet count, LDH, and NSE as independent prognostic factors. In subset multivariate analyses according to extent of disease, we found haemoglobin level, PS, NSE, and total WBC as significant prognostic indicators for survival in limited-stage disease (LD-SCLC), while PS, weight loss, LDH, number of metastases, liver metastases, and brain metastases were identified as independent prognostic factors in extensive-stage disease (EDSCLC). There was a significant correlation between serum LDH and NSE levels. In conclusion, gender, extent of disease, PS, weight loss, haemoglobin, WBC count, platelet count, LDH, and NSE were all found to be independent prognostic factors for SCLC survival. However, the prognostic value of these factors depends highly on whether all or subsets of SCLC patients are studied. (C) 2002 Elsevier Science Ireland Ltd. All rights reserved.
引用
收藏
页码:303 / 313
页数:11
相关论文
共 45 条
[31]   SMALL-CELL CARCINOMA OF THE LUNG - DERIVATION OF A PROGNOSTIC STAGING SYSTEM [J].
SAGMAN, U ;
MAKI, E ;
EVANS, WK ;
WARR, D ;
SHEPHERD, FA ;
SCULIER, JP ;
HADDAD, R ;
PAYNE, D ;
PRINGLE, JF ;
YEOH, JL ;
CIAMPI, A ;
DEBOER, G ;
MCKINNEY, S ;
GINSBERG, R ;
FELD, R .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (09) :1639-1649
[32]   THE PROGNOSTIC-SIGNIFICANCE OF PRETREATMENT SERUM LACTATE-DEHYDROGENASE IN PATIENTS WITH SMALL-CELL LUNG-CANCER [J].
SAGMAN, U ;
FELD, R ;
EVANS, WK ;
WARR, D ;
SHEPHERD, FA ;
PAYNE, D ;
PRINGLE, J ;
YEOH, J ;
DEBOER, G ;
MALKIN, A ;
GINSBERG, R .
JOURNAL OF CLINICAL ONCOLOGY, 1991, 9 (06) :954-961
[33]  
Sandler AB, 1997, SEMIN ONCOL, V24, P463
[34]   THE RELATIVE VALUE OF CONVENTIONAL STAGING PROCEDURES FOR DEVELOPING PROGNOSTIC MODELS IN EXTENSIVE-STAGE SMALL-CELL LUNG-CANCER [J].
SHEEHAN, RG ;
BALABAN, EP ;
COX, JV ;
FRENKEL, EP .
JOURNAL OF CLINICAL ONCOLOGY, 1990, 8 (12) :2047-2053
[35]  
SOUHAMI RL, 1985, CANCER RES, V45, P2878
[36]   PROGNOSTIC FACTORS IN SMALL-CELL CARCINOMA OF THE LUNG - AN ANALYSIS OF 1,521 PATIENTS [J].
SPIEGELMAN, D ;
MAURER, LH ;
WARE, JH ;
PERRY, MC ;
CHAHINIAN, AP ;
COMIS, R ;
EATON, W ;
ZIMMER, B ;
GREEN, M .
JOURNAL OF CLINICAL ONCOLOGY, 1989, 7 (03) :344-354
[37]   Pretreatment serum lactate dehydrogenase as additional staging parameter in patients with small-cell lung carcinoma [J].
Stokkel, MPM ;
van Eck-Smit, BLF ;
Zwinderman, AH ;
Willems, LNA ;
Pauwels, EKJ .
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 1998, 124 (3-4) :215-219
[38]   Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: Results from a randomized phase III trial with 5 years' follow-up [J].
Sundstrom, S ;
Bremnes, RM ;
Kaasa, S ;
Aasebo, U ;
Hatlevoll, R ;
Dahle, R ;
Boye, N ;
Wang, M ;
Vigander, T ;
Vilsvik, J ;
Skovlund, E ;
Hannisdal, E ;
Aamdal, S .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (24) :4665-4672
[39]  
Tamura M, 1998, ACTA MED OKAYAMA, V52, P105
[40]   Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide [J].
Turrisi, AT ;
Kim, K ;
Blum, R ;
Sause, WT ;
Livingston, RB ;
Komaki, R ;
Wagner, H ;
Aisner, S ;
Johnson, DH .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 340 (04) :265-271